CoAlign Innovations has announced that its AccuLIF XL lateral expandable interbody fusion devices have received marketing clearance from the FDA. A press release reported that the new product line addresses fusion procedures employing the lateral approach and joins the company’s range of AccuLIF TL (for transforaminal lumbar interbody fusion) and AccuLIF PL (for posterior lumbar interbody fusion) devices.
According to the company press release, the AccuLIF interbody system employs low-profile delivery and placement with controlled expansion to provide precise anatomical reconstruction of the spine during fusion surgery. As expansion occurs, a proprietary system of small titanium steps within the implant deploys to create a rigid, monolithic structure. Because it is inserted in its smallest form, the AccuLIF system is designed to minimise risk to nerve roots and damage to vertebral body endplates during placement.
Daniel Oberer, of Carolina Neurosurgery and Spine Associates in Charlotte, North Carolina, has used AccuLIF in numerous procedures. He said: “AccuLIF is simple to use and provides surgeons the ability to powerfully restore the lordosis and balance of the lumbar spine in a safe and effective manner. This work is often performed in tight spaces. Having the ability to ‘go in small’ and easily expand the device to the precise size required for that patient provides unparalleled control. AccuLIF is an exciting development for spinal surgeons.”